دورية أكاديمية
Microglia and macrophages in glioblastoma: landscapes and treatment directions.
| العنوان: | Microglia and macrophages in glioblastoma: landscapes and treatment directions. |
|---|---|
| المؤلفون: | Solomou G; Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Neurosurgery, Addenbrooke's Hospital, Cambridge, UK., Young AMH; Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Neurosurgery, Addenbrooke's Hospital, Cambridge, UK., Bulstrode HJCJ; Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, UK.; Department of Neurosurgery, Addenbrooke's Hospital, Cambridge, UK. |
| المصدر: | Molecular oncology [Mol Oncol] 2024 May 07. Date of Electronic Publication: 2024 May 07. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Hoboken, New Jersey : John Wiley & Sons, Inc. Original Publication: Amsterdam : Elsevier |
| مستخلص: | Glioblastoma is the most common primary malignant tumour of the central nervous system and remains uniformly and rapidly fatal. The tumour-associated macrophage (TAM) compartment comprises brain-resident microglia and bone marrow-derived macrophages (BMDMs) recruited from the periphery. Immune-suppressive and tumour-supportive TAM cell states predominate in glioblastoma, and immunotherapies, which have achieved striking success in other solid tumours have consistently failed to improve survival in this 'immune-cold' niche context. Hypoxic and necrotic regions in the tumour core are found to enrich, especially in anti-inflammatory and immune-suppressive TAM cell states. Microglia predominate at the invasive tumour margin and express pro-inflammatory and interferon TAM cell signatures. Depletion of TAMs, or repolarisation towards a pro-inflammatory state, are appealing therapeutic strategies and will depend on effective understanding and classification of TAM cell ontogeny and state based on new single-cell and spatial multi-omic in situ profiling. Here, we explore the application of these datasets to expand and refine TAM characterisation, to inform improved modelling approaches, and ultimately underpin the effective manipulation of function. (© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.) |
| References: | Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Suppl 5):v1–v95. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008‐2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella‐Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella‐Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T‐cell therapy for cancer. Immunol Rev. 2014;257(1):56–71. Robert C. A decade of immune‐checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. Buonfiglioli A, Hambardzumyan D. Macrophages and microglia: the cerberus of glioblastoma. Acta Neuropathol Commun. 2021;9(1):54. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD‐1 expression by tumour‐associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499. Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao C‐C, et al. Control of tumor‐associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22(5):729–740. Finch A, Solomou G, Wykes V, Pohl U, Bardella C, Watts C. Advances in research of adult gliomas. Int J Mol Sci. 2021;22(2):924. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. Bonaventura P, Shekarian T, Alcazer V, Valladeau‐Guilemond J, Valsesia‐Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol. 1987;74(3):269–277. Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease‐specific alterations of immune cells. Cell. 2020;181(7):1643–1660.e17. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2015;19(1):20–27. Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. T‐cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res. 2018;24(17):4175–4186. Ravi VM, Neidert N, Will P, Joseph K, Maier JP, Kückelhaus J, et al. T‐cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin‐10. Nat Commun. 2022;13(1):925. Antunes ARP, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single‐cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci. 2021;24(4):595–610. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res. 2016;4(2):124–135. Ma R‐Y, Black A, Qian B‐Z. Macrophage diversity in cancer revisited in the era of single‐cell omics. Trends Immunol. 2022;43(7):546–563. Bingle L, Brown NJ, Lewis CE. The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254–265. Li J, Kaneda MM, Ma J, Li M, Shepard RM, Patel K, et al. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response. Proc Natl Acad Sci USA. 2021;118(16):e2009290118. Zhai H, Heppner FL, Tsirka SE. Microglia/macrophages promote glioma progression. Glia. 2011;59(3):472–485. Matias D, Predes D, Filho PN, Lopes MC, Abreu JG, Lima FRS, et al. Microglia‐glioblastoma interactions: new role for Wnt signaling. Biochim Biophys Acta Rev Cancer. 2017;1868(1):333–340. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, Sliwa M, et al. Microglia‐derived TGF‐β as an important regulator of glioblastoma invasion—an inhibition of TGF‐β‐dependent effects by shRNA against human TGF‐β type II receptor. Oncogene. 2008;27(7):918–930. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103(4):351–355. Yeo AT, Rawal S, Delcuze B, Christofides A, Atayde A, Strauss L, et al. Single‐cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nat Immunol. 2022;23(6):971–984. Rajendran S, Hu Y, Canella A, Peterson C, Gross A, Cam M, et al. Single‐cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma. Cell Rep. 2023;42(3):112197. Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy via macrophage‐mediated T cell elimination. Nat Med. 2021;27(1):152–164. Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement‐dependent inflammation in cancer. Cell. 2015;160(4):700–714. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318(5848):287–290. Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol. 2017;28(7):1448–1456. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF‐1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264–1272. Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17(1):1–12. Kowal J, Kornete M, Joyce JA. Re‐education of macrophages as a therapeutic strategy in cancer. Immunotherapy. 2019;11(8):677–689. Gosselin D, Skola D, Coufal NG, Holtman IR, Schlachetzki JCM, Sajti E, et al. An environment‐dependent transcriptional network specifies human microglia identity. Science. 2017;356(6344):eaal3222. Galatro TF, Holtman IR, Lerario AM, Vainchtein ID, Brouwer N, Sola PR, et al. Transcriptomic analysis of purified human cortical microglia reveals age‐associated changes. Nat Neurosci. 2017;20(8):1162–1171. Geirsdottir L, David E, Keren‐Shaul H, Weiner A, Bohlen SC, Neuber J, et al. Cross‐species single‐cell analysis reveals divergence of the primate microglia program. Cell. 2019;179(7):1609–1622.e16. Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan‐cancer single‐cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184(3):792–809.e23. Aibar S, González‐Blas CB, Moerman T, Huynh‐Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: single‐cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083–1086. Young AM, Kumasaka N, Calvert F, Hammond TR, Knights A, Panousis N, et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. Nat Genet. 2019;5(6):12524–12525. Miller TE, Farran CAKE, Couturier CP, Chen Z, D'Antonio JP, Verga J, et al. Programs, origins, and niches of immunomodulatory myeloid cells in gliomas. bioRxiv. 2023. https://doi.org/10.1101/2023.10.24.563466. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV. Local self‐renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10(12):1538–1543. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841–845. Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, et al. C‐Myb+ erythro‐myeloid progenitor‐derived fetal monocytes give rise to adult tissue‐resident macrophages. Immunity. 2015;42(4):665–678. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Gene‐expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13(11):1118–1128. Haage V, Semtner M, Vidal RO, Hernandez DP, Pong WW, Chen Z, et al. Comprehensive gene expression meta‐analysis identifies signature genes that distinguish microglia from peripheral monocytes/macrophages in health and glioma. Acta Neuropathol Commun. 2019;7(1):20. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904. Blériot C, Chakarov S, Ginhoux F. Determinants of resident tissue macrophage identity and function. Immunity. 2020;52(6):957–970. Sierra A, de Castro F, del Río‐Hortega J, Iglesias‐Rozas JR, Garrosa M, Kettenmann H. The “Big‐Bang” for modern glial biology: translation and comments on Pío del Río‐Hortega 1919 series of papers on microglia. Glia. 2016;64(11):1801–1840. Réu P, Khosravi A, Bernard S, Mold JE, Salehpour M, Alkass K, et al. The lifespan and turnover of microglia in the human brain. Cell Rep. 2017;20(4):779–784. Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, et al. Microglial brain region−dependent diversity and selective regional sensitivities to aging. Nat Neurosci. 2016;19(3):504–516. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468(7321):253–262. Yona S, Kim K‐W, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38(1):79–91. Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004;18(9):998–1000. Priller J, Flügel A, Wehner T, Boentert M, Haas CA, Prinz M, et al. Targeting gene‐modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med. 2001;7(12):1356–1361. Biffi A, Palma MD, Quattrini A, Carro UD, Amadio S, Visigalli I, et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Investig. 2004;113(8):1118–1129. Abdelfattah N, Kumar P, Wang C, Leu J‐S, Flynn WF, Gao R, et al. Single‐cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13(1):767. Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, et al. Single‐cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017;18(1):234. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor evolution of glioma‐intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.e6. Guneykaya D, Ivanov A, Hernandez DP, Haage V, Wojtas B, Meyer N, et al. Transcriptional and translational differences of microglia from male and female brains. Cell Rep. 2018;24(10):2773–2783.e6. Thion MS, Low D, Silvin A, Chen J, Grisel P, Schulte‐Schrepping J, et al. Microbiome influences prenatal and adult microglia in a sex‐specific manner. Cell. 2018;172(3):500–516.e16. Gal‐Oz ST, Maier B, Yoshida H, Seddu K, Elbaz N, Czysz C, et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nat Commun. 2019;10(1):4295. Villa A, Gelosa P, Castiglioni L, Cimino M, Rizzi N, Pepe G, et al. Sex‐specific features of microglia from adult mice. Cell Rep. 2018;23(12):3501–3511. Ochocka N, Segit P, Walentynowicz KA, Wojnicki K, Cyranowski S, Swatler J, et al. Single‐cell RNA sequencing reveals functional heterogeneity of glioma‐associated brain macrophages. Nat Commun. 2021;12(1):1151. Ochocka N, Kaminska B. Microglia diversity in healthy and diseased brain: insights from single‐cell omics. Int J Mol Sci. 2021;22(6):3027. Gabrilovich DI. Myeloid‐derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8. Trovato R, Fiore A, Sartori S, Canè S, Giugno R, Cascione L, et al. Immunosuppression by monocytic myeloid‐derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer. 2019;7(1):255. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J‐I, Cheng P, et al. HIF‐1α regulates function and differentiation of myeloid‐derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439–2453. Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor‐associated macrophage differentiation. Immunity. 2016;44(2):303–315. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid‐derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–498. Bayik D, Zhou Y, Park C, Hong C, Vail D, Silver DJ, et al. Myeloid‐derived suppressor cell subsets drive glioblastoma growth in a sex‐specific manner. Cancer Discov. 2020;10(8):1210–1225. Bayik D, Lathia JD. Cancer stem cell–immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21(8):526–536. Kettenmann H, Hoppe D, Gottmann K, Banati R, Kreutzberg G. Cultured microglial cells have a distinct pattern of membrane channels different from peritoneal macrophages. J Neurosci Res. 1990;26(3):278–287. Madry C, Kyrargyri V, Arancibia‐Cárcamo IL, Jolivet R, Kohsaka S, Bryan RM, et al. Microglial ramification, surveillance, and interleukin‐1β release are regulated by the two‐pore domain K+ channel THIK‐1. Neuron. 2018;97(2):299–312.e6. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, et al. Microglia emerge from erythromyeloid precursors via Pu.1‐ and Irf8‐dependent pathways. Nat Neurosci. 2013;16(3):273–280. Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat Immunol. 2016;17(12):1397–1406. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. Proc National Acad Sci USA. 2016;113(12):E1738–E1746. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma–associated macrophages: laboratory investigation. J Neurosurg. 2009;110(3):572–582. Ruiz‐Moreno C, Salas SM, Samuelsson E, Brandner S, Kranendonk MEG, Nilsson M, et al. Harmonized single‐cell landscape, intercellular crosstalk and tumor architecture of glioblastoma. bioRxiv. 2022. https://doi.org/10.1101/2022.08.27.505439. Sankowski R, Böttcher C, Masuda T, Geirsdottir L, Sagar, Sindram E, et al. Mapping microglia states in the human brain through the integration of high‐dimensional techniques. Nat Neurosci. 2019;22(12):1–30. Böttcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, et al. Human microglia regional heterogeneity and phenotypes determined by multiplexed single‐cell mass cytometry. Nat Neurosci. 2019;22(1):78–90. Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, et al. Spatial and temporal heterogeneity of mouse and human microglia at single‐cell resolution. Nature. 2019;566(7744):388–392. Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. S100 proteins as an important regulator of macrophage inflammation. Front Immunol. 2018;8:1908. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106–4114. Chen H‐R, Sun Y‐Y, Chen C‐W, Kuo Y‐M, Kuan IS, Li Z‐RT, et al. Fate mapping via CCR2‐CreER mice reveals monocyte‐to‐microglia transition in development and neonatal stroke. Sci Adv. 2020;6(35):eabb2119. Domènech M, Hernández A, Plaja A, Martínez‐Balibrea E, Balañà C. Hypoxia: the cornerstone of glioblastoma. Int J Mol Sci. 2021;22(22):12608. Sousa C, Golebiewska A, Poovathingal SK, Kaoma T, Pires‐Afonso Y, Martina S, et al. Single‐cell transcriptomics reveals distinct inflammation‐induced microglia signatures. EMBO Rep. 2018;19(11):e46171. Mackaness GB. Cellular resistance to infection. J Exp Med. 1962;116(3):381–406. Celada A, Gray PW, Rinderknecht E, Schreiber RD. Evidence for a gamma‐interferon receptor that regulates macrophage tumoricidal activity. J Exp Med. 1984;160(1):55–74. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35. Jurga AM, Paleczna M, Kuter KZ. Overview of general and discriminating markers of differential microglia phenotypes. Front Cell Neurosci. 2020;14:198. Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2016;35(1):1–28. Hanisch U‐K, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387–1394. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–686. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor‐associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555. Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K, et al. Gliomas induce and exploit microglial MT1‐MMP expression for tumor expansion. Proc Natl Acad Sci USA. 2009;106(30):12530–12535. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. Pillars article: M‐1/M‐2 macrophages and the Th1/Th2 paradigm. J. Immunol. 2000. 164: 6166–6173. J Immunol. 2017;199(7):2194–2201. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour‐associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti‐cancer therapy. Eur J Cancer. 2006;42(6):717–727. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Glioblastoma‐infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2):e85841. Andersen RS, Anand A, Harwood DSL, Kristensen BW. Tumor‐associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy. Cancer. 2021;13(17):4255. Bulstrode H, Jones LM, Siney EJ, Sampson JM, Ludwig A, Gray WP, et al. A‐disintegrin and metalloprotease (ADAM) 10 and 17 promote self‐renewal of brain tumor sphere forming cells. Cancer Lett. 2012;326(1):79–87. Gjorgjevski M, Hannen R, Carl B, Li Y, Landmann E, Buchholz M, et al. Molecular profiling of the tumor microenvironment in glioblastoma patients: correlation of microglia/macrophage polarization state with metalloprotease expression profiles and survival. Biosci Rep. 2019;39(6):BSR20182361. Suvà ML, Tirosh I. The glioma stem cell model in the era of single‐cell genomics. Cancer Cell. 2020;37(5):630–636. Darmanis S, Sloan SA, Croote D, Mignardi M, Chernikova S, Samghababi P, et al. Single‐cell RNA‐seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 2017;21(5):1399–1410. Bulstrode H, Girdler GC, Gracia T, Aivazidis A, Moutsopoulos I, Young AMH, et al. Myeloid cell interferon secretion restricts Zika flavivirus infection of developing and malignant human neural progenitor cells. Neuron. 2022;110:3936–3951.e10. https://doi.org/10.1016/j.neuron.2022.09.002. Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Salié H, et al. Spatially resolved multi‐omics deciphers bidirectional tumor‐host interdependence in glioblastoma. Cancer Cell. 2022;40(6):639–655.e13. Gangoso E, Southgate B, Bradley L, Rus S, Galvez‐Cancino F, McGivern N, et al. Glioblastomas acquire myeloid‐affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;184(9):2454–2470.e26. Landry AP, Balas M, Alli S, Spears J, Zador Z. Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. Sci Rep. 2020;10(1):19542. Young AMH, Kumasaka N, Calvert F, Hammond TR, Knights A, Panousis N, et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. Nat Genet. 2021;53(6):861–868. Deczkowska A, Keren‐Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease‐associated microglia: a universal immune sensor of neurodegeneration. Cell. 2018;173(5):1073–1081. Franceschi C, Bonafè M, Valensin S, Olivieri F, Luca MD, Ottaviani E, et al. Inflamm‐aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908(1):244–254. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13. Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, et al. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. Brain Pathol. 2019;29(4):513–529. Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T, et al. Glioma‐associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015;10(2):e0116644. Conforti F, Pala L, Bagnardi V, Pas TD, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta‐analysis. Lancet Oncol. 2018;19(6):737–746. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835–849.e21. Bulstrode H, Johnstone E, Marques‐Torrejon MA, Ferguson KM, Bressan RB, Blin C, et al. Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators. Genes Dev. 2017;31(8):757–773. Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, et al. Reconstructing and reprogramming the tumor‐propagating potential of glioblastoma stem‐like cells. Cell. 2014;157(3):580–594. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, et al. Olig2‐regulated lineage‐restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007;53(4):503–517. Brooks LJ, Clements MP, Burden JJ, Kocher D, Richards L, Devesa SC, et al. The white matter is a pro‐differentiative niche for glioblastoma. Nat Commun. 2021;12(1):2184. Richards LM, Whitley OKN, MacLeod G, Cavalli FMG, Coutinho FJ, Jaramillo JE, et al. Gradient of developmental and injury response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity. Nat Cancer. 2021;2(2):157–173. Gangoso E, Southgate B, Bradley L, Rus S, Galvez‐Cancino F, McGivern N, et al. Glioblastomas acquire myeloid‐affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell. 2021;1–44. Hara T, Chanoch‐Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal‐like states in glioblastoma. Cancer Cell. 2021;39(6):779–792.e11. Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, et al. Osteopontin‐CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell. 2014;14(3):357–369. Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, et al. Osteopontin mediates glioblastoma‐associated macrophage infiltration and is a therapeutic target. J Clin Investig. 2018;129(1):137–149. Shi Y, Ping Y‐F, Zhou W, He Z‐C, Chen C, Bian B‐S‐J, et al. Tumour‐associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8(1):15080. Mathewson ND, Ashenberg O, Tirosh I, Gritsch S, Perez EM, Marx S, et al. Inhibitory CD161 receptor identified in glioma‐infiltrating T cells by single‐cell analysis. Cell. 2021;184(5):1281–1298.e26. Mulder K, Patel AA, Kong WT, Piot C, Halitzki E, Dunsmore G, et al. Cross‐tissue single‐cell landscape of human monocytes and macrophages in health and disease. Immunity. 2021;54(8):1883–1900.e5. Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA. Diverse requirements for microglial survival, specification, and function revealed by defined‐medium cultures. Neuron. 2017;94(4):759–773.e8. Dorion M, Yaqubi M, Murdoch HJ, Hall JA, Dudley R, Antel JP, et al. Systematic comparison of culture media uncovers phenotypic shift of primary human microglia defined by reduced reliance to CSF1R signaling. Glia. 2023;71(5):1278–1293. Horvath RJ, Nutile‐McMenemy N, Alkaitis MS, DeLeo JA. Differential migration, LPS‐induced cytokine, chemokine, and NO expression in immortalized BV‐2 and HAPI cell lines and primary microglial cultures. J Neurochem. 2008;107(2):557–569. Roesch S, Rapp C, Dettling S, Herold‐Mende C. When immune cells turn bad—tumor‐associated microglia/macrophages in glioma. Int J Mol Sci. 2018;19(2):436. Schafer ST, Mansour AA, Schlachetzki JCM, Pena M, Ghassemzadeh S, Mitchell L, et al. An in vivo neuroimmune organoid model to study human microglia phenotypes. Cell. 2023;186(10):2111–2126.e20. Caruso FP, Garofano L, D'Angelo F, Yu K, Tang F, Yuan J, et al. A map of tumor–host interactions in glioma at single‐cell resolution. Gigascience. 2020;9(9):giaa109. Majety M, Runza V, Lehmann C, Hoves S, Ries CH. A drug development perspective on targeting tumor‐associated myeloid cells. FEBS J. 2018;285(4):763–776. Jones CV, Ricardo SD. Macrophages and CSF‐1. Organogenesis. 2013;9(4):249–260. Stanley ER, Chitu V. CSF‐1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6(6):a021857. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249–262. Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF‐1R inhibition in gliomas. Science. 2016;352(6288):aad3018. Rao R, Han R, Ogurek S, Xue C, Wu LM, Zhang L, et al. Glioblastoma genetic drivers dictate the function of tumor‐associated macrophages/microglia and responses to CSF1R inhibition. Neuro Oncol. 2021;24(4):584–597. Stafford JH, Hirai T, Deng L, Chernikova SB, Urata K, West BL, et al. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization. Neuro Oncol. 2016;18(6):797–806. Butowski N, Colman H, Groot JFD, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557–564. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem‐like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31(4):591–606.e6. Qian B‐Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast‐tumour metastasis. Nature. 2011;475(7355):222–225. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid‐derived suppressor cells. Cancer Res. 2016;76(19):5671–5682. Flores‐Toro JA, Luo D, Gopinath A, Sarkisian MR, Campbell JJ, Charo IF, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci USA. 2020;117(2):1129–1138. Shono K, Yamaguchi I, Mizobuchi Y, Kagusa H, Sumi A, Fujihara T, et al. Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma. Sci Rep. 2020;10(1):15286. Felsenstein M, Blank A, Bungert AD, Mueller A, Ghori A, Kremenetskaia I, et al. CCR2 of tumor microenvironmental cells is a relevant modulator of glioma biology. Cancer. 2020;12(7):1882. Ferrara N, Gerber H‐P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676. Lee EQ, Duda DG, Muzikansky A, Gerstner E, Kuhn JG, Reardon DA, et al. Phase I and biomarker study of plerixafor and bevacizumab in recurrent high‐grade glioma. Clin Cancer Res. 2018;24(19):4643–4649. Thomas RP, Nagpal S, Iv M, Soltys SG, Bertrand S, Pelpola JS, et al. Macrophage exclusion after radiation therapy (MERT): a first in human phase I/II trial using a CXCR4 inhibitor in glioblastoma. Clin Cancer Res. 2019;25(23):6948–6957. Dang W, Xiao J, Ma Q, Miao J, Cao M, Chen L, et al. Combination of p38 MAPK inhibitor with PD‐L1 antibody effectively prolongs survivals of temozolomide‐resistant glioma‐bearing mice via reduction of infiltrating glioma‐associated macrophages and PD‐L1 expression on resident glioma‐associated microglia. Brain Tumor Pathol. 2021;38(3):189–200. Wei C, Wang B, Peng D, Zhang X, Li Z, Luo L, et al. Pan‐cancer analysis shows that ALKBH5 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including gliomas. Front Immunol. 2022;13:849592. van Rooijen N, Hendrikx E. Liposomes, methods and protocols, volume 1: pharmaceutical nanocarriers. Methods Mol Biol. 2009;605:189–203. Chen AX, Gartrell RD, Zhao J, Upadhyayula PS, Zhao W, Yuan J, et al. Single‐cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro‐tumor marker. Genome Med. 2021;13(1):88. Georgoudaki A‐M, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, et al. Reprogramming tumor‐associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15(9):2000–2011. Cheng X, Wang X, Nie K, Cheng L, Zhang Z, Hu Y, et al. Systematic Pan‐cancer analysis identifies TREM2 as an immunological and prognostic biomarker. Front Immunol. 2021;12:646523. Rodriguez‐Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O'Connor RS, et al. CAR‐T cell‐mediated depletion of immunosuppressive tumor‐associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12(1):877. Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. Ene CI, Kreuser SA, Jung M, Zhang H, Arora S, Moyes KW, et al. Anti–PD‐L1 antibody direct activation of macrophages contributes to a radiation‐induced abscopal response in glioblastoma. Neuro Oncol. 2019;22(5):639–651. Zhu Z, Zhang H, Chen B, Liu X, Zhang S, Zong Z, et al. PD‐L1‐mediated immunosuppression in glioblastoma is associated with the infiltration and M2‐polarization of tumor‐associated macrophages. Front Immunol. 2020;11:588552. Azambuja JH, Schuh RS, Michels LR, Iser IC, Beckenkamp LR, Roliano GG, et al. Blockade of CD73 delays glioblastoma growth by modulating the immune environment. Cancer Immunol Immunother. 2020;69(9):1801–1812. Lee J, Nicosia M, Silver DJ, Li C, Bayik D, Watson DC, et al. Sex‐specific T cell exhaustion drives differential immune responses in glioblastoma. bioRxiv. 2022. https://doi.org/10.1101/2022.08.17.503211. Wang G‐M, Cioffi G, Patil N, Waite KA, Lanese R, Ostrom QT, et al. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro Oncol. 2021;24(2):302–310. Lee J, Nicosia M, Hong ES, Silver DJ, Li C, Bayik D, et al. Sex‐biased T cell exhaustion drives differential immune responses in glioblastoma. Cancer Discov. 2023;13(9):2090–2105. Zheng Z, Zhang J, Jiang J, He Y, Zhang W, Mo X, et al. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi‐targeting liposomal codelivery. J Immunother Cancer. 2020;8(2):e000207. Ni X, Wu W, Sun X, Ma J, Yu Z, He X, et al. Interrogating glioma‐M2 macrophage interactions identifies Gal‐9/Tim‐3 as a viable target against PTEN‐null glioblastoma. Sci Adv. 2022;8(27):eabl5165. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour‐associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399–416. Kwon J, Bakhoum SF. The cytosolic DNA‐sensing cGAS–STING pathway in cancer. Cancer Discov. 2020;10(1):26–39. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674–678. Li T, Chen ZJ. The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215(5):1287–1299. Low JT, Chandramohan V, Bowie ML, Brown MC, Waitkus MS, Briley A, et al. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell. 2022;40(5):439–440. Palma MD, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, et al. Tumor‐targeted interferon‐α delivery by Tie2‐expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14(4):299–311. Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374(6573):1325–1326. Suryawanshi YR, Schulze AJ. Oncolytic viruses for malignant glioma: on the verge of success? Viruses. 2021;13(7):1294. Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer Res. 2018;78(3):718–730. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor‐specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4(6):568–580. Moyes KW, Lieberman NAP, Kreuser SA, Chinn H, Winter C, Deutsch G, et al. Genetically engineered macrophages: a potential platform for cancer immunotherapy. Hum Gene Ther. 2017;28(2):200–215. Lin R, Zhou Y, Yan T, Wang R, Li H, Wu Z, et al. Directed evolution of adeno‐associated virus for efficient gene delivery to microglia. Nat Methods. 2022;19(8):976–985. Niu Z, Chen G, Chang W, Sun P, Luo Z, Zhang H, et al. Chimeric antigen receptor‐modified macrophages trigger systemic anti‐tumour immunity. J Pathol. 2021;253(3):247–257. Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L, et al. Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022;14(656):eabn1128. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–953. Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MCM, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268–1274. van der Heide D, Weiskirchen R, Bansal R. Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front Immunol. 2019;10:2852. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF‐1R) signaling. Mol Med. 2012;18(3):519–527. da Fonseca ACC, Wang H, Fan H, Chen X, Zhang I, Zhang L, et al. Increased expression of stress inducible protein 1 in glioma‐associated microglia/macrophages. J Neuroimmunol. 2014;274(1–2):71–77. Viitala MK, Virtakoivu R, Tadayon S, Rannikko J, Jalkanen S, Hollmén M. Immunotherapeutic blockade of macrophage clever‐1 reactivates the CD8+ T cell response against immunosuppressive tumors. Clin Cancer Res. 2019;25(11):3289–3303. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–299. Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11(1):1508. Chinot OL, Wolfgang W, Warren M, Roger H, Frank S, Ryo N, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722. Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang‐2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti‐tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA. 2016;113(16):4476–4481. Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, et al. Dual inhibition of Ang‐2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci. 2016;113(16):4470–4475. Plate KH, Scholz A, Mittelbronn M, Harter P, Dumont D, van Slyke P, et al. Moving beyond VEGF: inhibing glioma angiogenesis by targeting the tie2/angiopoietin signaling pathway. Neuro Oncol. 2014;16(suppl_3):iii15. |
| فهرسة مساهمة: | Keywords: glioblastoma; glioma; immune; macrophages; microenvironment; microglia |
| تواريخ الأحداث: | Date Created: 20240507 Latest Revision: 20240507 |
| رمز التحديث: | 20240507 |
| DOI: | 10.1002/1878-0261.13657 |
| PMID: | 38712663 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!